Vertex Pharmaceuticals Inc (VRTX) - Total Assets
Based on the latest financial reports, Vertex Pharmaceuticals Inc (VRTX) holds total assets worth $27.42 Billion USD as of June 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Vertex Pharmaceuticals Inc - Total Assets Trend (1990–2025)
This chart illustrates how Vertex Pharmaceuticals Inc's total assets have evolved over time, based on quarterly financial data. Also see VRTX market cap for the company's overall valuation and market capitalisation.
Vertex Pharmaceuticals Inc - Asset Composition Analysis
Current Asset Composition (December 2025)
Vertex Pharmaceuticals Inc's total assets of $27.42 Billion consist of 42.9% current assets and 57.2% non-current assets. Review VRTX total liabilities to assess the company's total debt and financial obligations.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 19.5% |
| Accounts Receivable | $2.05 Billion | 7.9% |
| Inventory | $1.69 Billion | 6.5% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $424.20 Million | 1.6% |
| Goodwill | $1.09 Billion | 4.2% |
Asset Composition Trend (1990–2025)
This chart illustrates how Vertex Pharmaceuticals Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. See Vertex Pharmaceuticals Inc (VRTX) stock price for real-time trading data and today's change.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Vertex Pharmaceuticals Inc's current assets represent 42.9% of total assets in 2025, a decrease from 50.0% in 1990.
- Cash Position: Cash and equivalents constituted 19.5% of total assets in 2025, down from 47.8% in 1990.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 5.0% of total assets, an increase from 0.0% in 1990.
- Asset Diversification: The largest asset category is accounts receivable at 7.9% of total assets.
Vertex Pharmaceuticals Inc Competitors by Total Assets
Key competitors of Vertex Pharmaceuticals Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
argenx NV ADR
NASDAQ:ARGX
|
USA | $10.03 Billion |
|
Madrigal Pharmaceuticals Inc
NASDAQ:MDGL
|
USA | $1.26 Billion |
|
Shanghai RAAS Blood Products Co Ltd Class A
SHE:002252
|
China | CN¥37.98 Billion |
|
Halozyme Therapeutics Inc
NASDAQ:HALO
|
USA | $2.22 Billion |
|
Tubize-Fin
BR:TUB
|
Belgium | €1.99 Billion |
|
Aurinia Pharmaceuticals Inc
NASDAQ:AUPH
|
USA | $792.26 Million |
|
Nanobiotix
NASDAQ:NBTX
|
USA | $67.76 Million |
|
Innovita Biological Technology Co. Ltd. A
SHG:688253
|
China | CN¥2.23 Billion |
Vertex Pharmaceuticals Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 3.19 | 2.52 | 4.62 |
| Quick Ratio | 2.74 | 2.16 | 4.45 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $8.61 Billion | $6.29 Billion | $6.94 Billion |
Vertex Pharmaceuticals Inc - Advanced Valuation Insights
This section examines the relationship between Vertex Pharmaceuticals Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 6.56 |
| Latest Market Cap to Assets Ratio | 4.99 |
| Asset Growth Rate (YoY) | 16.0% |
| Total Assets | $26.14 Billion |
| Market Capitalization | $130.44 Billion USD |
Valuation Analysis
Premium Asset Valuation: The market values Vertex Pharmaceuticals Inc's assets at a significant premium (4.99x), suggesting investors see substantial growth potential or unique competitive advantages.
Rapid Asset Growth: Vertex Pharmaceuticals Inc's assets grew by 16.0% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Vertex Pharmaceuticals Inc (1990–2025)
The table below shows the annual total assets of Vertex Pharmaceuticals Inc from 1990 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | $26.14 Billion | +16.02% |
| 2024-12-31 | $22.53 Billion | -0.87% |
| 2023-12-31 | $22.73 Billion | +25.23% |
| 2022-12-31 | $18.15 Billion | +35.13% |
| 2021-12-31 | $13.43 Billion | +14.30% |
| 2020-12-31 | $11.75 Billion | +41.27% |
| 2019-12-31 | $8.32 Billion | +33.18% |
| 2018-12-31 | $6.25 Billion | +76.14% |
| 2017-12-31 | $3.55 Billion | +22.54% |
| 2016-12-31 | $2.89 Billion | +15.89% |
| 2015-12-31 | $2.50 Billion | +6.88% |
| 2014-12-31 | $2.34 Billion | +0.74% |
| 2013-12-31 | $2.32 Billion | -15.96% |
| 2012-12-31 | $2.76 Billion | +25.18% |
| 2011-12-31 | $2.20 Billion | +27.75% |
| 2010-12-31 | $1.73 Billion | -11.76% |
| 2009-12-31 | $1.96 Billion | +99.44% |
| 2008-12-31 | $980.48 Million | +63.01% |
| 2007-12-31 | $601.48 Million | -34.73% |
| 2006-12-31 | $921.58 Million | +67.87% |
| 2005-12-31 | $549.00 Million | +0.65% |
| 2004-12-31 | $545.45 Million | -24.70% |
| 2003-12-31 | $724.41 Million | -11.19% |
| 2002-12-31 | $815.72 Million | -11.83% |
| 2001-12-31 | $925.13 Million | +19.70% |
| 2000-12-31 | $772.88 Million | +232.56% |
| 1999-12-31 | $232.40 Million | -12.73% |
| 1998-12-31 | $266.30 Million | -9.91% |
| 1997-12-31 | $295.60 Million | +105.99% |
| 1996-12-31 | $143.50 Million | +44.95% |
| 1995-12-31 | $99.00 Million | -14.80% |
| 1994-12-31 | $116.20 Million | +90.49% |
| 1993-12-31 | $61.00 Million | +19.61% |
| 1992-12-31 | $51.00 Million | -10.68% |
| 1991-12-31 | $57.10 Million | +520.65% |
| 1990-12-31 | $9.20 Million | -- |
About Vertex Pharmaceuticals Inc
Vertex Pharmaceuticals Incorporated operates as a biotechnology company in the United States, Europe, and internationally. The company offers transformative medicines for people with serious diseases with a focus on specialty markets, such as cystic fibrosis (CF), sickle cell disease (SCD), transfusion dependent beta thalassemia (TDT), and acute pain. It markets TRIKAFTA/KAFTRIO for people with C… Read more